Market Trends of Global Rabies Vaccine Industry
This section covers the major market trends shaping the Rabies Vaccine Market according to our research experts:
The Purified Chick Embryo Cell Rabies Vaccine is Expected to Witness Growth Over the Forecast Period
The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who come into contact with animals such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, leading to rising cases of rabies. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine works by exposing a small dose of the rabies virus to the patient in order to develop immunity to the disease. There are some side effects, such as very high fever, tingling or prickly feelings in fingers or toes, weakness or unusual feelings in arms and legs, problems with balance or eye movement, and trouble while speaking or swallowing. This vaccine can be used for post-exposure or pre-exposure.
The rise in incidences of animal bites and rising government initiatives are expected to propel the growth of the segment studied over the forecast period. For instance, according to the report published by the Center for Disease Control (CDC) in March 2021, around 89.0 million dogs are in the United States and around 4.5 million dog bites occur each year in the United States.
Likewise, in April 2022, the disease prevention and control bureau, Department of Health, Philippines, awarded Metro Drugs Inc., a procurement contract for 2,500,000 doses of purified chick embryo cell rabies vaccine. The total approved budget for this contract is 200,000,000 PHP.
Therefore, such instances are expected to drive the demand for purified chick embryo cell rabies vaccine, thereby propelling the segment's growth over the forecast period.
North America is is Expected to Dominate the Rabies Vaccine Market Over the Forecast Period
The North America region is expected to dominate the overall rabies vaccine market throughout the forecast period. Increasing mortality due to rabies and an increasing number of dog bites and rabies cases in the region are expected to drive the market growth in this region. According to the data published by the Centers for Disease Control and Prevention (CDC) in April 2020, in the United States, nearly 5,000 cases of animal rabies are reported yearly to the CDC, and more than 90.0% of such cases occur in wildlife. In addition, the increasing number of deaths from rabies in North America is also anticipated to propel market growth. For instance, according to 2022 data by the Centers for Disease Control and Prevention, five people died of rabies in the United States in 2021. Therefore, such instances are expected to boost market growth in North America.
Moreover, key product launches, high concentration of market players and manufacturers' presence, acquisitions and partnerships among major players, and government initiatives toward rabies vaccination in the United States are some of the factors driving the market's growth. For instance, in September 2021, the Health Department, New York City Parks, the United States Department of Agriculture, and Cornell University partnered to distribute an oral rabies vaccine to immunize raccoons and protect them from infection with rabies in New York City.
Thus, the rise in the development of effective human rabies vaccines and increasing government initiatives are expected to boost market growth in North America over the forecast period.
